Sign in

    Kyle Krueger

    Research Analyst at Apollo Capital Management, L.P.

    Kyle Krueger is President and Managing Partner of Apollo Capital Management, L.P., focusing on micro-cap equity investments and hedge fund strategies since founding the firm in 1993. Krueger has covered small-cap and micro-cap companies such as Golden Books Family Entertainment, with a focus on high-risk, high-reward opportunities, and has participated in investment discussions related to firms like Houston American Energy Corp. Over his career, he served as Senior Vice President at Eagle Asset Management prior to Apollo, building a reputation for identifying promising emerging companies and delivering risk-adjusted returns in the micro-cap space. Krueger holds a bachelor's degree in finance from the University of Wisconsin, is a Chartered Financial Analyst (CFA), and has managed Apollo Capital Management, L.P. as a registered investment advisor.

    Kyle Krueger's questions to ISR leadership

    Kyle Krueger's questions to ISR leadership • Q2 2022

    Question

    Kyle Krueger of Apollo Capital Management, L.P. asked for assurance regarding the Cesium-131 supply chain from Russia amidst geopolitical tensions, inquired about the availability of alternative global sources, and questioned whether the recent Omicron surge caused similar procedure displacements as seen in past COVID-19 waves.

    Answer

    CEO Lori Holmes-Woods provided assurance on the Russian isotope supply, citing a long-standing relationship that has remained undisrupted through past geopolitical events. She stated they see no complications and that business continues as usual, with potential minor inconveniences like payment methods being the only foreseeable issue. She noted that while they constantly evaluate other global reactors, alternatives like a previous U.S. source have been cost-prohibitive. Regarding the Omicron surge, she confirmed that procedure volumes are impacted when hospitals face staffing shortages and reduce nonessential surgeries, but they are also seeing quicker upticks during lulls as a backlog of patients seeks treatment.

    Ask Fintool Equity Research AI